Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Why Tilray Stock Is Bouncing Back Today

What happened

Shares of Tilray, Inc.(NASDAQ:TLRY) are jumping today, up 15.3% as of 10:55 a.m. EDT, after the Canadian marijuana producer announced earlier in the morning that it had exported medical cannabis to three hospitals in Australia to help critically ill children suffering from epilepsy.

So what

Did news that Tilray has exported medical cannabis to Australia justify the stock's rebound today? No. The announcement wasn't anything really new for Tilray. The company has shipped medical cannabis to Australia in the past, with its first export dating back to March 2017.

Image source: Getty Images.

Arcview Market Research and BDS Analytics estimate that the Australian medical marijuana market will generate only around $3 million in sales this year and $48 million by 2022. That's not nearly enough to warrant Tilray gaining close to $1.5 billion in market cap Tuesday morning.

So what's really going on with Tilray's jump today? We're likely seeing continued volatility from a short squeeze that drove the marijuana stock up more than 830% from Aug. 1 through Sept. 19 and the aftermath of that short squeeze ending, which caused Tilray's share price to plunge around 50% over the three-day period prior to Tuesday's rebound.

Now what

The best thing for investors to do now is to sit back and take a deep breath. It's best to stay away from Tilray while the stock's wild ride continues.

Over the long run, Tilray should have solid business prospects as medical and recreational marijuana markets across the world open up more. However, the stock's big move today is further evidence that Tilray remains too hot to handle for long-term investors. Don't be surprised if shares jump up and down erratically for a while to come.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Author

Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights